IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
Portfolio Pulse from
IO Biotech's therapeutic cancer vaccine, IO102-IO103, combined with KEYTRUDA®, shows promising results in a Phase 2 study for metastatic lung cancer, with a 55% overall response rate and 81% disease control rate. The safety profile is consistent with previous studies.
November 07, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IO Biotech's IO102-IO103 vaccine, in combination with KEYTRUDA®, shows promising results in a Phase 2 study for metastatic lung cancer, with a 55% overall response rate and 81% disease control rate. The safety profile is consistent with previous studies.
The positive results from the Phase 2 study of IO102-IO103 in combination with KEYTRUDA® are likely to boost investor confidence in IO Biotech, potentially leading to a positive impact on the stock price. The high response and disease control rates, along with a consistent safety profile, are significant achievements in cancer treatment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100